CN107206007B - 用于治疗肺高血压的方法 - Google Patents

用于治疗肺高血压的方法 Download PDF

Info

Publication number
CN107206007B
CN107206007B CN201680010141.9A CN201680010141A CN107206007B CN 107206007 B CN107206007 B CN 107206007B CN 201680010141 A CN201680010141 A CN 201680010141A CN 107206007 B CN107206007 B CN 107206007B
Authority
CN
China
Prior art keywords
group
compound
och
pulmonary hypertension
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680010141.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107206007A (zh
Inventor
L·巴特
M·坎廷棱
E·M·瓦里斯
S·R·巴特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reviva Pharmaceuticals Inc
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of CN107206007A publication Critical patent/CN107206007A/zh
Application granted granted Critical
Publication of CN107206007B publication Critical patent/CN107206007B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680010141.9A 2015-01-12 2016-01-11 用于治疗肺高血压的方法 Active CN107206007B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562102470P 2015-01-12 2015-01-12
US62/102,470 2015-01-12
PCT/US2016/012873 WO2016115039A1 (en) 2015-01-12 2016-01-11 Methods for treating pulmonary hypertension

Publications (2)

Publication Number Publication Date
CN107206007A CN107206007A (zh) 2017-09-26
CN107206007B true CN107206007B (zh) 2021-08-10

Family

ID=56406257

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680010141.9A Active CN107206007B (zh) 2015-01-12 2016-01-11 用于治疗肺高血压的方法

Country Status (5)

Country Link
US (1) US10441590B2 (cg-RX-API-DMAC7.html)
EP (1) EP3244896B1 (cg-RX-API-DMAC7.html)
JP (1) JP6787926B2 (cg-RX-API-DMAC7.html)
CN (1) CN107206007B (cg-RX-API-DMAC7.html)
WO (1) WO2016115039A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3749324B1 (en) 2017-12-28 2025-11-05 Reviva Pharmaceuticals, Inc. Arylpiperazine compound for use to treat pulmonary fibrosis
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102413830A (zh) * 2009-02-26 2012-04-11 雷维瓦药品公司 利用芳基哌嗪衍生物的组合物、合成及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4613598A (en) * 1984-03-13 1986-09-23 Mitsubishi Chemical Industries Limited Piperazine derivatives and their acid addition salts
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
NZ555491A (en) 2005-01-03 2010-01-29 Univ Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
AR063302A1 (es) * 2006-10-13 2009-01-21 Otsuka Pharma Co Ltd Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla.
RU2497819C2 (ru) 2007-05-21 2013-11-10 Ривайва Фармасьютикалс, Инк. Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина
TWI373336B (en) * 2007-06-15 2012-10-01 Univ Kaohsiung Medical Kmup-1 capable of treating hypertension
EP2299814A4 (en) * 2008-05-27 2011-06-15 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR USE OF ANTIPSYCHOTICS ON PIPERAZINE BASIS
MX2011004284A (es) * 2008-10-22 2011-06-21 Sam Amer & Co Inc Metodo para tratar la hipertension arterial pulmonar.
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
WO2015157451A1 (en) 2014-04-08 2015-10-15 Reviva Pharmaceuticals, Inc. Methods for treating attention deficit hyperactivity disorder

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102413830A (zh) * 2009-02-26 2012-04-11 雷维瓦药品公司 利用芳基哌嗪衍生物的组合物、合成及方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats;Eiji Hironaka等;《Cardiovascular Research》;20031231;第60卷;第692–699页 *

Also Published As

Publication number Publication date
US20180125851A1 (en) 2018-05-10
EP3244896B1 (en) 2024-06-12
HK1244448A1 (zh) 2018-08-10
EP3244896A4 (en) 2018-08-29
JP6787926B2 (ja) 2020-11-18
CN107206007A (zh) 2017-09-26
WO2016115039A1 (en) 2016-07-21
JP2018502156A (ja) 2018-01-25
EP3244896C0 (en) 2024-06-12
US10441590B2 (en) 2019-10-15
EP3244896A1 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
EP3259271B1 (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
JPH09507219A (ja) α−２−アドレノセプター作動剤として有用な７−（２−イミダゾリニルアミノ）キノリン化合物
EP3244896B1 (en) Methods for treating pulmonary hypertension
JP2025518413A (ja) アルテミシニン誘導体、その製造方法及び使用
US12053477B2 (en) Methods for treating pulmonary fibrosis
WO2015157451A1 (en) Methods for treating attention deficit hyperactivity disorder
JP7569953B2 (ja) Ｓｓｔｒ４アゴニスト及びその塩の調製のための方法並びに使用のための用量レジメン
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
HK1245081A1 (zh) 用於治疗阿尔茨海默病的方法
CN107206006A (zh) 用于治疗与帕金森病相关联的精神病的方法
HK1244448B (en) Methods for treating pulmonary hypertension
TW201622715A (zh) 治療自發性肺纖維化之方法
HK40038590A (en) Methods for treating pulmonary fibrosis
JP2000500765A (ja) ロイコトリエン拮抗剤としてのジオール含有キノリン誘導体
HK40066388A (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
GB2644610A (en) New methods
HK1241361B (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1243061A1 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1244448

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant